Get started
Author

Miranda Davies

Observed names: Davies, Miranda, M Davies, M N Davies, M. Davies
ORCID: 0000-0003-2949-8378
Observed ORCID: 0000-0003-2949-8378
OpenAlex ID: A5010753379
Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment
2020 · Vicki Osborne, Miranda Davies, et al. · Drug Safety · 70
PDF
Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment
2020 · Miranda Davies, Vicki Osborne, et al. · Drug Safety · 69
PDF
Safety Profile of Modafinil Across a Range of Prescribing Indications, Including Off-Label Use, in a Primary Care Setting in England: Results of a Modified Prescription-Event Monitoring Study
2013 · Miranda Davies, Lynda Wilton, et al. · Drug Safety · 38
Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective
2025 · Amy Bobbins, Miranda Davies, et al. · British Journal of Clinical Pharmacology · 29
Use of atomoxetine and suicidal ideation in children and adolescents: Results of an observational cohort study within general practice in England
2016 · M. Davies, A. Coughtrie, et al. · European Psychiatry · 20
Safety Profile of Esomeprazole
2008 · Miranda Davies, Lynda V Wilton, et al. · Drug Safety · 19
How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine
2020 · Saad Shakir, Samantha Lane, et al. · Drug Safety · 15
PDF
Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study
2020 · Alison Evans, Miranda Davies, et al. · BMJ Open · 11
PDF
The International Working Group on New Developments in Pharmacovigilance: Advancing Methods and Communication in Pharmacovigilance
2024 · Dawn Cooper, Robert W. Platt, et al. · Clinical Therapeutics · 10
PDF
Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management
2020 · Vicki Osborne, Miranda Davies, et al. · BMJ Evidence-Based Medicine · 10
PDF
Utilisation of extended release quetiapine (Seroquel XL™): Results from an observational cohort study in England
2016 · V. Osborne, M. Davies, et al. · European Psychiatry · 10
Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in England
2017 · Vicki Osborne, Miranda Davies, et al. · Drug Safety · 8
Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study
2021 · Sigal Kaplan, Rachel Levy-Toledano, et al. · Frontiers in Endocrinology · 7
PDF
Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice
2020 · Luis Alberto García-Rodríguez, Mari-Ann Wallander, et al. · Expert Opinion on Drug Safety · 6
PDF
Safety and utilisation of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine: a UK post-authorisation active surveillance study
2025 · Alison Evans, Debabrata Roy, et al. · BMJ Open · 4
Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
2020 · Alison Evans, Miranda Davies, et al. · PLoS ONE · 4
PDF
A 12-Month Modified Prescription Event Monitoring Report for Travoprost
2007 · M N Davies, N Paiba, et al. · Drug Safety · 3
A Scoping Review of Case-Level Causality Assessment Tools Developed Between 2008 and 2023; Strengths, Weaknesses and Potential Future Improvements
2026 · Dawn Cooper, Mohammed Toseef Ansari, et al. · Drug Safety · 2
Convalescent Plasma in treatment of COVID-19: A review of evidence for a living systematic benefit-risk assessment
2020 · Miranda Davies, Samantha Lane, et al. · medRxiv · 2
PDF
Observational assessment of safety in seroquel (OASIS): a specialist cohort event monitoring (SCEM) study in England
2020 · Vicki Osborne, Miranda Davies, et al. · Therapeutic Advances in Psychopharmacology · 1
TARGET-EU: Effectiveness of BNT162b2 mRNA COVID-19 vaccine in healthy individuals or with stable pre-existing medical conditions against SARS-CoV-2 infection
2026 · Andaur Navarro, Constanza L., Mohammadi, Sima, et al. · Zenodo (CERN European Organization for Nuclear Research)
TARGET-EU: Dapagliflozin and major adverse cardiovascular events in type 2 diabetes
2026 · Lasys, Tomas, Mohammadi, Sima, et al. · Zenodo (CERN European Organization for Nuclear Research)
TARGET-EU: Comparison of single-device vilanterol/fluticasone furoate with other single-device inhaled corticosteroid and long-acting beta agonist combinations in the risk of pneumonia in adolescents with asthma
2026 · Lasys, Tomas, Mohammadi, Sima, et al. · Zenodo (CERN European Organization for Nuclear Research)
TARGET-EU: The risk of angiooedema and other safety events in heart failure patients treated with sacubitril/valsartan compared to angiotensin-converting enzyme inhibitors
2026 · Lasys, Tomas, Mohammadi, Sima, et al. · Zenodo (CERN European Organization for Nuclear Research)
TARGET-EU: Tolvaptan and risk associated to hepatotoxicity in autosomal dominant polycystic kidney disease
2026 · Lasys, Tomas, Mohammadi, Sima, et al. · Zenodo (CERN European Organization for Nuclear Research)
Works count: 31
Citation count: 338
H-index: 10
I10-index: 11
Year
Topic
Type